Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Cash Flow (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Net Cash Flow for 4 consecutive years, with -$7.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 118.96% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 million through Dec 2025, up 249.78% year-over-year, with the annual reading at $12.4 million for FY2025, 249.78% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$7.3 million at Orchestra BioMed Holdings, down from $23.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $77.6 million in Q2 2022, with the low at -$77.2 million in Q4 2022.
  • Average Net Cash Flow over 4 years is $1.5 million, with a median of -$350000.0 recorded in 2023.
  • The sharpest move saw Net Cash Flow tumbled 564.37% in 2024, then surged 1129.55% in 2025.
  • Over 4 years, Net Cash Flow stood at -$77.2 million in 2022, then soared by 114.87% to $11.5 million in 2023, then crashed by 129.13% to -$3.3 million in 2024, then tumbled by 118.96% to -$7.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$7.3 million, $23.3 million, and $401000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.